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Abstract
Integrin α6β4 is a membrane protein which is expressed in both normal and cancerous epithelia. In normal cells, it is involved
in adhesion to the basal membrane. In carcinomas, however, it takes on cell signaling roles related to survival and migration. Due
to its key role in cancer progression, it is now being considered as a therapeutic target. This paper examines how we can affect
integrins, with a specific focus on integrin α6β4, to reinforce their ability to prevent migration of cancer cells and progress toward
metastasis.
Methods
Data was collected using ProQuest, PubMed databases,
and the National Library of Medicine. The images and diagrams can be found in the research articles referenced.
Introduction
Integrin α6β4 is a membrane protein found on the basal
side of epithelial cells. It is a member of the integrin family of proteins. Integrins are heterodimers which are imbedded in cell membranes and signal allosterically; ligand
binding to extracellular binding sites causes conformational changes in the integrin which ultimately affect their
cytoplasmic domains. These domains link to the cell’s
cytoskeleton and thereby perform signal transduction.
As much as their signaling works outward-inward, their
signaling also works inward-outward. Integrins’ position
in the cell makes them a key component in signaling, cell
migration, and cell adhesions. Each integrin has a distinct,
specific function, and, therefore, they have diverse ligands.
Many integrins, including α6β4, can be turned on or off
and need to be activated by tyrosine kinases or growth
factors in order to bind to their ligands.
Integrin α6β4 is different from other integrins because
it has a unique β subunit, with an atypically long cytoplasmic domain which connects to the keratin intermediate
filament system, as opposed to the microfilament system.
The α subunit binds to its ligand, laminin 332, in the extracellular matrix. Through mediating the interactions with
laminin and keratin, integrin α6β4 is the core component
of the hemidesmosome, a protein complex which attaches basal epithelial cells to the basement membrane.
Normally, integrin α6β4 is involved in hemidesmosomes and contributes to tissue stability. Cancerous cells,
however, lack hemidesmosomes and integrin α6β4 is localized at the leading edges of metastasized carcinoma
cells. Integrin α6β4 interacts with many cancer-related
growth factors such as epidermal growth factor receptor
(EGFR). Significantly, integrin α6β4 activates phosphoinositide 3-OH kinase (PI3K), a key signaling molecule for
carcinoma invasions.
Because of integrins’ unique positioning in the cell and
in cell signaling, they are highly involved in development
of cancers. At times, integrins can inhibit pathways, and

at times they can activate pathways instead. Therefore,
integrins should be considered as a possible target for
treating cancers. Integrin α6β4 can be considered as a
model, as it attaches cells to the basement membrane and
can contribute to invasion and metastasis of carcinomas.
However, before examining cancerous cells, it is necessary to understand the behavior of integrins in normal
epithelial tissue.
Integrin α6β4 in Regular Cells
In healthy epithelial cells, integrin α6β4 occupies a central
place in the hemidesmosome, a protein complex which
connects epithelial cells to the basement membrane.
There are two kinds of hemidesmosomes: type 1, which
is found in stratified and pseudostratified epithelia (such
as in the epidermis) and type 2, which is found in simple
epithelia (such as in the intestine). In the more complex
type 1 hemidesmosomes, integrin α6β4 facilitates the interactions with most of the proteins involved, including
the intracellular proteins plectin and BP180, the transmembrane proteins BP230 and tetraspanin CD151, and
the extracellular protein laminin 332, which is part of the
basal lamina (Walko et al, 2015). In the simpler type 2
hemidesmosomes, the only components are plectin, laminin, and integrin α6β4, which mediates the interactions
between the other two. Integrin α6β4’s presence even in
these simplified hemidesmosome proves that it is essential for the adhesion of epithelial cells to the basement
membrane below (de Pereda et al, 2009). Additionally,
mice missing β4 exhibited pathology similar to junctional
epidermolysis bullosa, a human disease characterized by
fragile skin that blisters quickly due to the basal layer’s
separation from the basement membrane. The epithelial tissues of the mice, both simple and stratified, lacked
hemidesmosomes and did not adhere normally (Dowling
et al, 1996).
The α6 subunit is homologous to other integrin α subunits. α6, like many other integrin protomers, associates
with more than one β subunit. For instance, α6β1 is an
integrin found in the retina and cortex, and is linked to
disorders of those tissues (Hynes, 2002).When it is found
in epithelial cells, however, it is exclusively associated with
β4 and binds to laminin as its ligand. α6 is made up of
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1,055 amino acids, with the first 1,011 outside the cell,
36 in the transmembrane region, and 19 in the cytoplasm.
(Tamura et al, 1990). The amino domain has 7 homologous repeats, which were found to make up a 7-bladed
β propeller (Kamata et al, 2001). It is made up of two
polypeptides, a heavy chain and a light chain, which originated from one polypeptide but which were cleaved using
post-translational modification. They are joined by a disulfide bridge, similar to α5, αv, α11b, and αP52. However,
it does not contain the insert domain near the amino terminus that other α subunits possess (Tamura et al, 1990).
β4 has 710 amino acids in its extracellular region, with
cysteine conservation of that region the same as that of
other β subunits. It has a 23 amino acids in its transmembrane region and has 1089 amino acids in its cytoplasmic
region (Tamura et al, 1990). The cytoplasmic domain is
made up of 5 globular domains. From the membrane toward the inside of the cell, they are: a Na+- Ca+ Calx-β
exchange motif, a pair of fibronectin type III domains
(FnIII-1,2), and another pair of fibronectin domains (FnIII3,4). Between the two pairs of FnIII domains, there is a
flexible connecting segment (CS), and after the second
set, there is a c-terminal tail (Walko et al, 2015). There
are 5 possible N-glycosylation sites, all of which are glycosylated (Tamura et al, 1990).
Over time, a clearer picture of α6β4 has been formed.
Scanning electron microscopy revealed that both subunits have a large globular head and a stalk portion which
then traverses the cell membrane. The two protomers
complex by binding their heads together (Luo, 2007). α6’s
amino domain contains a 7-bladed β propeller domain,
which is made up of 7 four-strand β sheets similar to
those found in other integrins, which is topped by a ligand
binding site. However, it lacks the “insert” domain, otherwise known as a Von Willebrand Factor A domain, which
has a MIDAS (a cation coordination site), that is found
imbedded in the propeller of the majority of integrins
(Kamata et al, 2001).This makes sense because only integrins that are exclusive to chordates have this domain, and
α6β4 is homologous to that of more primitive species.
When an integrin has this insert domain, cation coordination to the MIDAS site causes a conformational change in
the protein, pulling part of the α6 head further down and
allowing the ligand to bind to its binding site.
Ligand binding occurs differently in integrins lacking this
insert domain like α6β4. In this integrin, β4 has its own
insert domain with a MIDAS motif, which, when inactive,
is in contact with α6’s propeller. When the C-terminus
of β4 moves downward, or when a cation binds to the
MIDAS, it pulls the rest of the protein, exposing more of
the propeller surface to allow for a greater affinity for
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ligand binding (Hynes, 2002). When priming and ligand
binding occur, a large-scale conformational change overcomes both subunits. In their resting, low-affinity phase,
both subunits’ stalks are bent downward in the middle
in a genuflected position, with their intracellular domains
touching. When ligand binds, the subunits straighten in a
switchblade-like motion and the legs separate, exposing
binding surfaces.This is one instance of allosteric signaling
in integrins (Luo, 2007).
The majority of connections in the hemidesmosome
occur with the large intracellular domain of β4. The four
FnIII domains have a conserved hydrophobic core, with
9 out of 11 identical residues, but their outer surfaces,
which are exposed to solvent, are entirely different, so
they can bind to different groups (Alonso-Garcia et al,
2015). The critical interaction within the hemidesmosome is between β4 and plectin. Plectin binds to the IFs
in the cell, while α6’s interaction with β4 allows it bind
to its ligand, laminin. The two proteins join at β4’s second
Fn-III domain and at plectin’s actin-binding domain (ABD).
This complex is formed by three sets of ionic interactions: between R1225 of β4 and D151 of plectin, between
R1281 of β4 and E95 of plectin, and between E1242 of
β4 and R98 of plectin. Missense mutations in one of the
residues involved in these salt bridges disturbs the interaction with plectin. The first 7 residues of the connecting
segment also play a part in this interaction by extending
the binding surface of the Fn-III domain. The first FnIII
domain also contributes to the interaction through a hydrophobic pocket made up of I1163, Y1187 and C1190,
which interacts with an R-side chain in plectin. When β4
binds to plectin, a conformational change is triggered in
β4; in unbound β4, part of the CS is folded over FnIII-2
and engages in antiparallel H-bonding with it. In bound β4,
that part of the CS is unbent and may reveal binding sites
for other proteins in the hemidesmosome, like BP230
and BP180 (de Pereda et al, 2009).
Integrin α6β4 in Wounded Cells
Although integrin α6β4 is associated with cell adhesion,
it is also involved in signaling pathways associated with
cell migration, differentiation, and proliferation. These
processes assist in healing wounds. This is indicated by
its localization to the front edge of cells migrating into a
wound. Additional proof can be seen in an experiment
involving A549 (adenocarcinomic human alveolar basal
epithelial) cells. When the β4 gene was knocked down,
the cells migrated less processively than the controls.
When the α6 gene was knocked down, the cells migrated
both less processively and more slowly. Examination of
keratinocytes has revealed that wild-type keratinocytes
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move on a straight line along their matrix of laminin, while
β4-deficient keratinocytes move in a circular fashion. All
of this shows that integrin α6β4 plays an essential role in
healing wounds (Colburn, Jones, 2017).
In order for cells to migrate toward a wound bed, the
hemidesmosomes need to disassemble, a process that
begins from the cytoplasmic domain and then continues in the extracellular domain. β4 serine residues are
first phosphorylated by tyrosine kinases to separate β4
from its binding partner, plectin; this is stimulated by
epidermal growth factor (EGF) (Mainero et al, 1996), as
well as protein kinase C (Rabinovitz, et. al. 1999). After
β4’s phosphorylation, the rest of the connections in the
hemidesmosome are then severed (Walko et al, 2015). At
this point, α6β4 detaches from the intermediate filament
(keratin) cytoskeleton and instead associates with the
actin cytoskeleton. It becomes involved in the formation
of lamellae and filopodia, which are protrusions of the cell
membrane that give the cell motility.
Epithelial cells involved in wound healing are similar to
metastasizing carcinoma cells, allowing comparisons to be
drawn between them. In both cases, there is a lack of
polarization in the cells and an induction of migration.
(Rabinovitz et al, 2015). Importantly, many of the same
mechanisms are involved, including the coordination with
growth factors, the disassociation from the hemidesmosome, and the formation of lamellae and filopodia.
Integrin α6β4 in Carcinoma
In many types of carcinomas, high levels of integrin α6β4
correlate with the invasiveness of the cancer, as well as
the patient prognosis. For example, in basal-type breast
cancer, which is a highly aggressive form of breast cancer, a β4 “gene signature” was associated with decreased
time to tumor recurrance and a smaller chance of patient survival (Lu, 2008). Other research shows similar
correlation with elevated β4 expression in other invasive
phenotypes of squamous cell carcinomas, including some
kinds of bladder (Grossman et al, 2000), cervical (Jeffers
et al, 1997), head and neck (Kurokawa et al, 2008), lung
(Stewart et al, 2016), and pancreatic (Cruz-Montseratte
et al, 2007) carcinomas. Interestingly, although thyroid
cells do not normally express α6β4, it has been found
in thyroid carcinomas (Kitajiri et al, 2002). In addition to
overexpression of α6β4, it is also located throughout
multiple layers of cells in tumors, as opposed to its normal concentration of the basal side of the epithelial cells
(van Waes et al, 1995).
However, in some varieties of cancer, integrin α6β4
expression is correlated with tumor suppression. For
example, in prostate carcinomas, α6β4 is downregulated

(Nagle et al, 1995). Also, when α6β4 was added to cells
from the RKO cell line, a colon carcinoma cell line which
is missing β4, the result was partial G1 arrest and apoptosis (Clarke et al, 1995). Because this integrin is associated
with both growth and migration, but with suppression as
well, it may be hard to target as a treatment for cancer. In
order to examine treatment options, an in-depth look at
the mechanism of action of integrin-implicated signalling
pathways must take place.
Integrin α6β4 Signalling Mechanism
When integrin α6β4 is released from hemidesmosomes,
it leads to altered signals promoting tumor cell growth,
invasion and metastasis (Lipscomb, Mercurio, 2005). Once
free from the hemidesmosome interaction, integrin α6β4
can bind or cooperate with many different molecules or
growth factor receptors to activate various cell signalling pathways. Integrin α6β4 can bind directly to its regular ligand, laminin, activating both phosphatidylinositol
3-kinases (PI3K) and RhoA small GTPases. Alternatively,
it can cooperate with various growth factor receptors,
including those in the EGFR (epidermal growth factor
receptor) family, such as ErbB-1,2, and 3 (Guo et al,
2006), as well as c-Met (Chung et al, 2004), Ron, LPA1
and LPA2 (O’Connor et al, 2012). This leads to intensification of signaling through PI3K, AKT, MAPK and the Rho
small GTPases, as depicted in Figure 1. Integrin α6β4 can
also promote tumor progression through transcriptional
regulation. It has been shown to increase the expression
of invasive and metastatic proteins such as the epithelial to mesenchymal transition (EMT)-associated protein
S100A4 (Stewart, O’Connor, 2015).

Figure 1 (Stewart, O’Connor, 2015)
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Integrin α6β4 is involved in the PI3K pathway, a signaling pathway known for promoting carcinoma progression
(Shaw et al, 1997). However, the cytoplasmic domain of
the integrin β4 subunit does not have a consensus-binding motif for the regulatory subunit of PI3K , so direct activation of the pathway does not seem possible. One possible mechanism for integrin β4-mediated activation of
PI3K involves insulin receptor substrate-1 and −2 (IRS-1
and IRS-2), which act as signaling intermediates facilitating
integrin α6β4-mediated PI3K activation. Ligation of integrin α6β4 promotes phosphorylation of IRS-1 and IRS-2,
and then activation of PI3K (Shaw, 2001). Additionally, integrin α6β4 cooperates with ErbB-2 to promote PI3Kdependent invasion (Gambaletta et al, 2000). Integrin
α6β4 has also been shown to localize to lipid rafts in the
membrane, allowing it to recruit other receptor tyrosine
kinases, and thus allowing it to activate PI3K (GagnouxPalacios et al, 2003).
ErbB-2 is one of the members of the EFGR family which
signals for invasion and aggression in breast carcinoma.
Integrin α6β4 has been shown to associate with ErbB-2 in
multiple breast carcinoma cell lines (Falcioni et al, 1997).
Although ErbB-2 is implicated upstream of PI3K, ErbB-2
does not have a binding site for the regulatory subunit of
PI3K. ErbB-2, as a receptor tyrosine kinase, must dimerize
with another receptor to function. In this case, it dimerizes with an ErbB-3, a different EGFR receptor. Erb-B3 has
a binding site for PI3K’s regulatory subunit, and this heterodimer is a strong activator of PI3K. There is a positive
association between integrin α6β4 and ErbB-3 expression in patient-derived tumors (Folgiero et al, 2008).
Other receptor tyrosine kinases that cooperate with
integrin α6β4 include c-Met, which is activated by HGF
(hepatocyte growth factor); a complex of α6β4 and
c-Met was shown to promote HGF dependent invasion
(Trusolino et al, 2001). Ron, a tyrosine kinase receptor
closely related to c-Met, has been shown to form a complex with integrin α6β4 that induces hemidesmosome
disassembly and the relocation of integrin α6β4 to motility structures. Ron activation is important in pancreatic
carcinoma progression, and it interacts with the integrin
β4 subunit in this setting to disrupt the association between integrin β4 and plectin (Yu et al, 2012).
Integrin α6β4 also upregulates the Rho family of small
GTPases. The Rho family of small GTPases control the
reorganization of the actin cytoskeleton required for cell
motility (Machacek, et. al. 2009). The activation of RhoA
leads to lamellae formation, as well as the generation of
contraction forces that enable cell migration (O’Connor
et al, 2000). Significantly, RhoA generally controls the generation of stress fibers rather than lamellae formation,
48

suggesting that integrin α6β4 changes RhoA’s function to
facilitate tumor invasion (Stewart, O’Connor, 2015).
Integrin α6β4 can also stimulate angiogenesis by enhancing signaling through the protein kinase ERK and
transcription factor NF-κB. Studies using knockout mice
carrying a deletion in the signaling domain of the integrin β4 subunit displayed reduced angiogenesis in a retinal
neovascularization model, and developed smaller and less
vascularized tumors after subcutaneous implantation.The
same study demonstrated that the integrin β4 subunit
could promote both bFGF (basic fibroblast growth factor)- and VEGF (vascular endothelial growth factor)-induced angiogenesis by enhancing signaling through ERK
and NF-κB (Nikolopoulos et al, 2004).
Cell Survival and Tumor Suppression
Returning to the paradox above, integrin α6β4 promotes
either cell survival or apoptosis, depending on context.
For instance, in normal epithelial cells, integrins promote
survival when in contact with the extracellular matrix.
However, once separated, the loss of integrin signaling can
inhibit cell growth and promote anoikis, a form of apoptosis (Ruoslahti, Reed, 1994). Similarly, in cancer, at times
integrin α6β4 acts as a promoter of cell survival, while at
times it acts as a tumor suppressant.
To discover why these two different scenarios exist,
a group studied two cell lines. In the RKO cell line, β4
led to increased apoptosis, while in the MDA-MB-435
cell line, β4 did not induce apoptosis. They discovered
that the difference lay in the cells’ p53, a protein which is
often implicated in cancer when mutated. RKO cells have
wild-type p53, while MDA-MB-435 cells have mutant p53
(Bachelder et al, 1999). Integrin α6β4 can trigger apoptosis through p53 activation in cells harboring wild-type
p53; however, in carcinoma cells deficient in p53, integrin
α6β4 promotes cell survival by activating the PI3K pathway and through growth factors such as VEGF (vascular
endothelial growth factor). This discovery suggests that
tumors expressing high levels of integrin α6β4 in conjunction with mutated p53 are resistant to apoptosis and
will therefore display a more aggressive clinical course.
Interestingly, an association between p53 mutations and
integrin α6β4 overexpression is present in a number of
aggressive human malignancies, including basal-like breast
cancer, head and neck squamous cell carcinoma, and
pancreatic ductal adenocarcinoma (Stewart, O’Connor,
2015).
Treating Carcinomas Through Integrin
Modification
Since integrins were discovered as molecules involved in
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cancer, there has been a move to target them in cancer
treatment. However, drugs developed to impact integrins
have largely been unsuccessful. It’s possible that it is because the integrin-targeting drugs may only have moderate affinity in vivo for integrin receptors, as shown by the
doses used in clinical trials. Another reason may be that
integrin antagonists work best when inhibiting early metastatic spread and not in advanced cancer stages, when
cancer cells are already widespread (Paolillo, Schinelli,
2017)
Another issue may be that the wrong integrins have
been targeted. Not all integrins have been thoroughly
explored as therapeutic targets, including integrin α6β4.
That said, a common issue for all the integrins is that
cells express multiple integrins at the same time, and if
one would be targeted in treatment, the others might
compensate for it.That explains why the drugs given were
well tolerated with few ill effects, but also did not impact the cancer. The solution would be to try and impact
multiple integrins at once, but that might be difficult to
achieve in a patient (Alday-Parejo et al, 2019).
The issue may also not be the stage or affinity, but the
drug target itself. Most drugs designed for integrins target
the integrin-ligand interaction; in this case, they would
try to competitively inhibit the interaction between the
integrin’s extracellular side and laminin 332.This could be
a problem because integrins signal allosterically, so if an
inhibitor would bind to the integrin’s ligand binding pocket, it could actually turn on the integrin and the signalling
cascades could begin. The cytoplasmic domain may be a
better option (Alday-Parejo et al, 2019).
Thus far, one group has worked on an inhibitor targeting the cytoplasmic side of integrin α6β4. They found
that curcumin, a yellow pigment derived from turmeric,
inhibited the interaction between the cytoplasmic tail and
EGFR, which is implicated in the PI3K pathway related
to survival, invasion, and metastasis. EGFR is activated
when the residues Y1068 and Y1045 are phosphorylated;
when α6β4 was knocked out, there was significantly less
phosphorylation, showing a connection between the two
structures.They added curcumin to other cells and found
that it had a similar effect on EGFR phosphorylation as
knocking down α6β4. The hemidesmosomes in cells with
curcumin remained stable upon stimulation with EGF
(Soung, Chung, 2011).
Discussion/Conclusion
Integrin α6β4 plays an essential part in both regular and
cancerous cells. Significantly, it contributes to the PI3K
pathway, related to cancer aggression and survival. Integrin
α6β4 should definitely be studied, both as a diagnostic

tool and as a target for therapeutic intervention. As discussed above, it is a predictor of the cancer’s severity and
can be used in a diagnostic setting. More research should
be put into targeting its intracellular interaction with
growth factors so that these pathways can be inhibited.
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